把引起自身免疫性疾病的自身反应性T细胞或导致同种移植排斥反应的同种反应性T细胞看作是致病性T细胞,将它们活化并灭活后,以疫苗的形式免疫动物,诱导机体产生针对致病性T细胞或同种反应性T细胞的免疫应答,从而消除或减轻这些细胞的致病作用;表现为对自身免疫性疾病和对同种移植物排斥的防治作用。这一方法称为T细胞疫苗接种（TCV）。TCV的作用机制是上调免疫网络中的抑制性作用,产生了抗独特型T细胞,抑制了相应克隆T细胞的作用。用TCR多肽免疫替代TCV亦是有效的方法。TCV或TCR多肽免疫对防治自身免疫性疾病有潜在的应用价值,对控制同种排斥反应也是一条有效措施。 Autoreactive T cells that cause autoimmune diseases or alloreactive T cells that cause allograft rejection are considered to be pathogenic T cells. After they are activated and inactivated, the animals are immunized as a vaccine, Induce the body to produce an immune response against pathogenic T cells or alloreactive T cells, thereby eliminating or alleviating the pathogenic effects of these cells; exhibiting a preventive and therapeutic effect on autoimmune diseases and allograft rejection. This method is called T cell vaccination (TCV). The mechanism of action of TCV is to upregulate the suppressive effect in the immune network, producing anti-idiotypic T cells and inhibiting the corresponding clonal T cells. It is also an effective method to immunize TCV with TCR polypeptide. Immunization with TCV or TCR peptides has potential value in the prevention and treatment of autoimmune diseases and is also an effective measure to control allograft rejection.